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Background: The aim of the study was to evaluate the relationship between the area of isopters obtained using
semi-automated kinetic perimetry (SKP) and Vigabatrin dosage in epilepsy patients with pretreatment baseline
examination during 2-years of the follow-up.
Methods: 29 epilepsy patients were included into the study, but 15 individuals were excluded due to cognitive
impairment, intracranial pathologies or eye diseases. Finally, 14 patients were examined with SKP before VGB
treatment and after 6, 12, 18, and 24 months. Reaction time (RT)-corrected areas of three isopters (III4e, I4e and I2e)
were measured for each of five examinations and compared intra-individually during 2-years period. Additionally,
six epilepsy patients on other antiepileptic drugs were examined five times with SKP as a control.
Results: There was a significant decrease of I2e, I4e and III4e isopters’ area during the follow-up of two years.
Correlation was found between the I2e isopter’s area and both cumulative dose and mean daily dose of VGB. With
increasing RT, there was decreasing of all isopters’ area in patients receiving VGB. In epilepsy patients who were not
receiving VGB, there were no significance differences in isopters’ area during follow-up.
Conclusion: There was attenuation of area of III4e, I4e and I2e isopters obtained with SKP during a period of
2 years. RT, the cumulative dose and the mean daily dose of VGB influenced isopters' area obtained with SKP.
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Vigabatrin (VGB) (Sabril, Hoechst Marion Russel/Aventis
Ltd) is a selective irreversible inhibitor of the gamma-
aminobutric acid -transaminase [1] used in the man-
agement of partial epilepsy if it cannot be controlled
satisfactorily by conventional therapy. Since 1997 many
studies have reported symmetrical bilateral constriction of
the visual field (VF) associated with VGB intake [2] with
normal appearance of the optic nerve head and retina [3].
The incidence rate of VGB-induced concentric constric-
tion of the VF varies with the method used to assess the
VF, ranging from 17% [4] to 92% [5] of exposed adults.* Correspondence: katarzynanowomiejska@mailcity.com
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article, unless otherwise stated.Perimetry seems to be the best method to screen and
monitor the visual function in patients taking VGB, how-
ever, there is no consensus in the literature as to the
optimum perimetric test and there is no good method to
quantify the VF loss. In clinical practice most of the pa-
tients treated with VGB are examined with static perim-
etry within 60° [6] or 30° [7] or 24° [8] of eccentricity.
However, there is lack of validated scoring system for
analysing supra-threshold screening programmes and un-
acceptable poor reliability indices have been observed
while examining epilepsy patients with full threshold auto-
mated static perimeter [3,9]. Monitoring of visual function
to understand the occurrence and manage the potential
consequences of peripheral VF defects is now required for
all patients who receive VGB [10].entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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automatic assessment of the entire (90˚) VF using
Goldmann stimuli, which are presented along selected
meridians with a constant angular velocity [11]. Results
of SKP have been shown to be comparable to those of
Goldmann manual kinetic perimetry [12] and static au-
tomated perimetry [13]. The major advantage of SKP is
the standardisation of parameters and the ability to
measure the isopters’ area in square degrees (deg2) and
to consider reaction time (RT) in milliseconds (ms).
The aim of this prospective study was to evaluate the re-
lationship between the area of isopters obtained using SKP
and Vigabatrin dosage during a 2-years follow-up period
in patients with pretreatment baseline examination.Methods
Participants
The study was a prospective and observational case series.
It was approved by the Ethics Committee of the Medical
University in Lublin and performed in accordance with
the ethical standards laid down in the 2008 Declaration of
Helsinki.Table 1 Demographic data and drug history of each of 14 pa







1 54 M 1.0 0.9 1800 1470
2 23 F 1.0 1.0 1450 1050
3 41 F 1.0 1.0 1000 1230
4 53 F 1.0 1.0 1000 750
5 48 F 1.0 1.0 1500 1305
6 34 M 1.0 1.0 2100 1440
7 27 M 1.0 1.0 1900 1710
8 56 F 1.0 1.0 1000 1290
9 59 M 0.7 1.0 2300 1365
10 49 F 1.0 1.0 2000 1740
11 48 M 1.0 1.0 1500 11305
12 31 F 1.0 1.0 1000 300
13 39 F 1.0 1.0 1000 6000












SKP-semi-automated kinetic perimetry.A total of 29 adult patients with focal epilepsy and a
clinical presentation of complex partial seizures with or
without secondary generalisation (mean disease duration
of 10 ± 4 years and mean seizure frequency of 5 ± 4/month
at the study inclusion) were prospectively identified and
selected by the neurologist from the Neurology Outpatient
Clinic in Lublin and referred to the Department of
Ophthalmology in Lublin. Inclusion criteria were as fol-
lows: at least 18 years of age, refractive errors of < 3 D
sphere and < 1 D cylinder, transparent ocular media, pupil
diameter more than 3 mm. The exclusion criteria were
symptoms or signs of diseases other than epilepsy, in par-
ticular relating to visual function and patients who had
had prior treatment that could have affected visual func-
tion. Overall 15 patients of the cohort were excluded. Nine
patients were excluded due to cognitive deficiency. Two
patients were excluded due to the ophthalmological ab-
normalities (optic nerve head drusen and cataract) and
four patients - due to the intracranial pathology (encephal-
itis, cerebral palsy and stroke) causing hemianopic defects.
Consequently, 14 patients (8 females, 6 males) remained
in the study. The details of the demographic data (age,














27 25 OCZ Normal
24 24 VPA, LTG Normal
21 24 OCZ Mildly abnormal
23 25 VPA Normal
29 24 CBZ, CLZ Normal
23 23 VPA, CBZ Normal
29 25 VPA, CBZ Normal
27 21 CBZ Normal
24 24 VPA Mildly abnormal
24 21 CBZ Normal
24 22 CBZ Normal
11 14 CBZ Normal
15 12 CBZ Normal
25 25 CBZ Normal
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of the follow-up, other antiepileptic drugs) and classifi-
cation of VF results of each patient are shown in a table
(Table 1). Additionally, six patients never exposed to VGB
treated with other antiepileptic drugs were examined five
times as a control group. Median visual acuity of this
group was 1.0, mean age was 38 years (range 26–51 years).
Patients had to have the diagnosis of epilepsy confirmed,
according to the recommendations of the International
League Against Epilepsy [14]. All patients underwent a
standard blood analysis (liver and renal function, serum
electrolytes, basic haematological indices) performed not
longer than 1 week prior to the enrollment. All patients
were carefully interviewed and clinically examined by a
neurologist. The seizure frequency was monitored and cal-
culated based on the available diaries provided by patients.
Disease duration was estimated by determining the time
from the first reported seizure. The mean age of patients
at the time of inclusion was 42 years (range 23–59 years).
On initial testing written informed consent was taken
from all participants after explaining the nature of the
study. All patients underwent a full ophthalmological
examination including visual acuity testing, slit lamp
examination, applanation tonometry and fundus examin-
ation. The mean of the best-corrected visual acuity of right
eye was 0.97 (range 0.7-1.0) and 0.99 (range 0.9-1.0) of the
left eye. The visual acuity remained stable during consecu-
tive visits. None of the patients reported VF constriction.
Medication
All patients received VGB as an adjunctive treatment to
other antiepileptic drugs according clinical indications in
order to increase seizure control. They all responded with
good seizure control and gave consent to continue the
treatment, being aware of potential side effects relating to
visual function. Patients were examined first before starting
treatment with VGB. The mean of the daily dose of VGB
was 1535 mg/d (range 1000–2300 mg/d). At the time of
the study, VGB was combined with other antiepileptic
drugs: carbamazepin (CBZ) (64%), clonazepam (CLZ) (7%),
oxcarbazepin (OCZ) (14%), valproid acid (VPA) (35%),
lamotriginum (LTG) (7%). Patients from the control group
received CBZ 67%, CLZ (33%) or gabapentinum (17%).
The mean duration of VGB therapy was 23 months
(range 11–25 months). To calculate the cumulative dose
(in grams) the daily dose was multiplied by the duration
of therapy and then divided by 1000. The mean cumula-
tive dose of VGB was 1164 g (range 300–1740 g) in this
group.
VF examination and analysis
VF examinations were performed with the SKP im-
plemented in Octopus 101 instrument (Haag-Streit
Inc., Koeniz, Switzerland). The same examiner (KN)performed all VF examinations. Both eyes were tested in
all patients with the right eye tested before the left. The
patients had no previous experience in the VF examin-
ation. Fourteen patients were examined five times: at base-
line (i.e. before treatment) and 6, 12, 18, and 24 months
after VGB intake. The mean examination duration was
11 minutes for both eyes (range 6–16 minutes). For the
control group the examination duration was 12 min for
both eyes (range 9–15 min).
During the VF examination the patient was instructed
to look at the fixation target and push the button as
quickly as possible when perceiving the stimulus. Stimuli
V4e, III4e and I4e according to the Goldmann classifica-
tion moving with the constant angular velocity of 3 de-
grees per second were used. The blind spot was assessed
using I4e stimulus. RT was assessed by vectors located
within intact areas of III4e isopter – two in the centre
and two in the periphery of the VF. The periphery of the
VF was examined without correction, an appropriate
near correction was used for the central 30°. Fixation
was monitored by the examiner using the video display
of the instrument. The area of each isopter was cor-
rected for RT and measured automatically in deg2 after
each examination. The areas of three isopters (III4e, I4e
and I2e) were measured for each of five examinations
and compared intra-individually for each patient.
VF constriction was assessed by two observers, masked
to the patients’ clinical status, according to the classifica-
tion proposed by Wild and Kälviäinen [15,16] and used
by Vanthalo [17] This classification is based on the tem-
poral region of the VF. Three stages were described: (I)
normal VF - extending out of 70˚ in the temporal merid-
ian, (II) mildly abnormal - between 70˚ and 50˚ of the
temporal meridian, (III) severely abnormal – less than
50˚ of the temporal meridian.
Statistical analysis
As both eyes of each patient were examined, the area of
isopters and RT of right eyes and left eyes were analyzed
separately. Shapiro-Wilk test showed that the distribution
of the data is not normal, nonparametric test Friedman
Chi2 ANOVA was used for multiple comparisons of each
isopter area and RT during the follow-up. As post-hoc
analysis nonparametric Wilcoxon test was used to show
differences in isopters’ area between visits. The Spearman
correlation was assessed between the VF loss and age, RT,
the mean daily dose, and cumulative dose of VGB. Statis-
tical computations were performed using STATISTICA
10.0 (StatSoft, Poland) software.
Results
For the right eye there were significant differences be-
tween consecutive examinations for area of isopters:
III4e (p = 0.031) (Figure 1), I4e (p = 0.003) (Figure 2) and
Figure 1 The area of III4e isopter in square degrees (medians, 25 and 75% quartiles and maximum and minimum values) of right eyes
of patients on Vigabatrin treatment during 2- years follow-up period (five consecutive SKP examinations).
Figure 2 The area of I4e isopter in square degrees (medians, 25 and 75% quartiles and maximum and minimum values) of right eyes
of patients on Vigabatrin treatment during 2- years follow-up period (five consecutive SKP examinations).
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http://www.biomedcentral.com/1471-2415/14/56I2e (p = 0.022) (Figure 3). For the right eye the mean area
of III4e isopter was 13145.34 deg2 (standard deviation
[SD] 1695.16 deg2) during the first examination and
11917.47 deg2 (SD 2590.82 deg2) during the fifth exa-
mination (Figure 1). The mean area of I4e isopter was
9863.88 deg2 (SD 1874.24 deg2) during the first examin-
ation and 8795.90 deg2 (SD 2522.65 deg2) during the fifth
examination (Figure 2). The mean area of I2e isopter was
4120.17 deg2 (SD 1244.25 deg2) during the first examin-
ation and 3829,05 deg2 (SD 1804.21 deg2) during the fifth
examination (Figure 3).
For the right eye there were significant differences in
area of III4e isopter between the first and second exam-
ination (Z = 1.98; p = 0.05) and the first and fourth
examination (Z = 2.73; p = 0.006). For I4e isopter the dif-
ferences were significant between the first and third
examination (Z = 2.73; p = 0.006) and between the first
and fourth examination (Z = 2.54; p = 0.01). For I2e isop-
ter the differences were significant between the first and
third examination (Z = 2.67; p = 0.008) and between the
first and fourth examination (Z = 2.23; p = 0.03).
For the left eye, there were also significant differences
between consecutive examinations for III4e (p = 0.001)
(Figure 4), I4e (p = 0.044) (Figure 5) and I2e (p = 0.008)
(Figure 6) isopters. For the left eye the mean area of III4e
isopter was 13445.71 deg2 (SD 1575.41 deg2) during the
first examination and 12161.48 deg2 (SD 2314.69 deg2)
during the fifth examination (Figure 4). The mean area ofFigure 3 The area of I2e isopter in square degrees (medians, 25 and
of patients on Vigabatrin treatment during 2- years follow-up periodI4e isopter was 10217.37 deg2 (SD 1762.10 deg2) during
the first examination and 8841,68 deg2 (SD 2331.54 deg2)
during the fifth examination (Figure 5). The mean area of
I2e isopter was 4152.29 deg2 (SD 1044.73 deg2) during the
first examination and 3853.79 deg2 (SD 1552.76 deg2) dur-
ing the fifth examination (Figure 6).
For the left eye there were significant differences in
area of III4e isopter between the first and fourth exam-
ination (Z = 2.42; p = 0.02) and the first and fifth examin-
ation (Z = 2.10; p = 0.04). For I4e isopter the differences
were significant between the second and fourth examin-
ation (Z = 2.54; p = 0.01) and between the second and
fifth examination (Z = 2.10; p = 0.04). For I2e isopter the
differences were significant differences between the third
and fourth examination (Z = 2.79; p = 0.005).
Hence, the area of all isopters decreased significantly
between 5 examinations during 2-years follow-up both
for the right and left eye.
In epilepsy patients who were not receiving VGB,
there were no significance differences (p > 0.05) in III4e,
I4e and I2e isopters’ area between examinations during
follow-up period.
Correlation was found between the area of all isopters
and individual RT for III4e R = −0.69; p = 0.002), for I4e
(R = −0.57; p = 0.004),for I2e (R = −0.43; p = 0.004) for
the right eye and for III4e (R = −0. 61; p = 0.002), I4e
(R = −0.52; p = 0.017) and I2e (R = −0.49; p = 0.024) for
the left eye.75% quartiles and maximum and minimum values) of right eyes
(five consecutive SKP examinations).
Figure 4 The area of III4e isopter in square degrees (medians, 25 and 75% quartiles and maximum and minimum values) of left eyes
of patients on Vigabatrin treatment during 2- years follow-up period (five consecutive SKP examinations).
Figure 5 The area of I4e isopter in square degrees (medians, 25 and 75% quartiles and maximum and minimum values) of left eyes of
patients on Vigabatrin treatment during 2- years follow-up period (five consecutive SKP examinations).
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Figure 6 The area of I2e isopter in square degrees (medians, 25 and 75% quartiles and maximum and minimum values) of left eyes of
patients on Vigabatrin treatment during 2- years follow-up period (five consecutive SKP examinations).
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cumulative dose of VGB for I2e isopter for the right eye
(R = −0.63; p = 0.001) and I2e for the left eye (R = −0.46;
p = 0.031).
Correlation was also found between the isopters’ area
and the mean daily dose of VGB for I4e (R = −0.49; p =
0.02) and I2e (R = −0.78; p = 0.00001) for the right eye
and for III4e (R = −0.42; p = 0.042) and I2e (R = −0.73;
p = 0.008) for the left eye. Thus, with increasing cumula-
tive dose of VGB there is decreasing of area of I2e isop-
ter for both eyes. With increasing mean daily dose of
VGB there is decreasing of I4e and I2e isopters’ area for
the right eye and decreasing of III4e and I2e isopters’
area for the left eye.
There was no correlation found between isopters’ area
and age of patients for the right eye (III4e p = 0.332, I4e
p = 0.107 and I2e p = 0.617) and for the left eye (III4e
p = 0.998, I4e p = 0.324 and I2e p = 0.461).
After careful individual qualitative analysis of each pa-
tient VF series by two masked graders, the VFs of 2 of
14 patients (14%) - patient number 3 and number 9 -
were classified as VAVFL (Figure 7a-d). The VF constric-
tion was mild in the temporal meridian according to the
classification of Wild and Kalvainen, with a depression
observed nasally. VGB was discontinued in both two pa-
tients who developed VAVFL.
The mean RT was 940.9 ms (range 310–2500 ms) for the
whole group. The differences in RT between examinationswere not significant for the right eye (p = 0.400) (Figure 8)
and for the left eye (p = 0.111) (Figure 9).
There was a correlation found between RT and area of
III 4e (R = −0,46) , I4e (R = −0,52) and I 2e (R = −0,52)
isopters. Thus, the longer RT, the smaller isopter’s area.
Discussion
This is the first prospective investigation dealing with re-
peated SKP examinations over a 2-years follow-up in
patients undergoing VGB therapy with the baseline exam-
ination performed before therapy.
There is lack of adequate prospective studies with VGB
pre-treatment baseline examinations in the literature.
Thus, the natural history of the VF loss is not known. The
guidelines regarding monitoring VGB patients published
by the Royal College of Ophthalmologists recommended
pretreatment baseline VF examination and follow-up with
VF examinations every 6 months during first three years
of treatment [10]. However, 1/2 of the individuals who
were initially screened for our study were not able to per-
form perimetry due to cognitive impairment. It is already
known that approximately 20% patients exposed to VGB
are unable to perform perimetry [18]. In the study of
Kinirions [19] 152 patients were initially identified, but fi-
nally 93 were analysed. Forty-six patients were unsuitable
for VF assessment because of moderate or severe learning
disability and 11 patients had VFs that were thought to be
unreliable.
Figure 7 Results of five consecutive examinations of semi-automated kinetic perimetry (Octopus 101) of a patient with
Vigabatrin-attributable visual field loss. Mean daily dose 1950 mg, cumulative dose 1230 g, duration of VGB treatment - 24 months. Other
antiepileptic drug: oxcarbazepin.
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coherence tomography - OCT) might also be obtained
in these patients instead of VF testing, as Wild [20]and other authors [21] found attenuation of peripapil-
lary RNFL in patients exhibiting constriction of the
VF.
Figure 8 Reaction time values in milliseconds (medians, 25 and 75% quartiles, maximum and minimum values) of right eyes during
five SKP examinations of patients taking Vigabatrin during 2-years period.
Figure 9 Reaction time values in milliseconds (medians, 25 and 75% quartiles, maximum and minimum values) of left eyes during five
SKP examinations of patients taking Vigabatrin during 2-years period.
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loss were retrospective, cross-sectional and analyzed the
VF results in patients examined first after having started
VGB therapy [8,16,21]. The advantage of our study is
that it was prospective, performed using standardized
method by the same examiner for five times during 2-
years period. Quantitative assessment of the manual
Goldmann kinetic VF is a very difficult task to perform.
In previous studies with kinetic Goldmann perimetry I4e
and V4e isopters [3] or III4e, and I2e isopters were used
[8,19,22]. During manual kinetic perimetry isopters are
drawn manually by the examiner, the area of isopters
can be measured by planimetry but this procedure is
complicated and time-consuming [3,4]. Other methods
have also been used to quantitatively assess the results
of manual Goldmann kinetic perimetry, such as the
Esterman grid [4] and the mean radial degree (radius of
isopters) [3,8,18,22]. The major advantage of SKP is that
it is examiner-independent and enables constant speed
of movement of the stimulus, automated measurement
of area of isopters in deg2, moreover, it provides an elec-
tronic documentation of the results. SKP is also pre-
ferred by patients more than manual Goldmann kinetic
perimetry. In the study comparing SKP with manual
Goldmann perimetry in patients with advanced VF loss
[12] a questionnaire was given to assess the preference
of the patients. SKP was preferred by 52%, Goldmann
was preferred by 32%, 16% had no preferrence. SKP was
mostly preferred among patients with concentric con-
striction of the VF due to retinitis pigmentosa. In our
opinion SKP can be recommended as a method of as-
sessment of the visual function in the monitoring epi-
lepsy patients taking VGB.
The number of patients in our study is relatively low
(14), but the follow-up period was comparatively long -
24 months. Newman and colleagues examined one hun-
dred patients at baseline, but after 18 months only 22
patients remained in the study [3]. In the study of
Kinirons the mean follow-up time of the 41 patients was
2.2 years and the mean number of visual assessments
was two [19]. Paul and co-workers observed 15 patients
every 3 months for one year after 2-years period of VGB
treatment [8]. In the most recent study regarding VAVFL
14 patients were monitored over a 10-year period with
Goldmann manual kinetic perimetry (isopters I2e, I4e
and I4e) [23]. In this study there was a high degree of
variability observed in VF size between successive test
sessions.
In the present study we found a significant decrease of
the three isopters’ area during follow-up. Moreover, rela-
tionship was found between I2e isopters’ area and both
the cumulative dose and the mean daily dose of VGB.
Cumulative VGB dose has been already found the most
significant predictor of the VF loss [4,23,24]. However, inthe studies of Kalviainen [15], Kinirions [19] and Newman
[3] no correlation was found between VF loss and either,
the duration of VGB exposure or the cumulative dose. In
the study performed by Conway and colleagues [25] max-
imum daily VGB dose was taken as an independent vari-
able and was found as the most reliable indicator to
exhibit VF defects. However, in this investigation only cen-
tral VF was examined with automated static perimetry.
VF constriction was identified in 2 of 14 patients (14%),
based on the assessment of two masked observers. The VF
loss was mild according to the classification proposed by
Wild and Kälviäinen [14,15] and in agreement with previ-
ous findings was more predominant nasally. Thus, it was
not recognized by patients as the temporal and inferior
fields are often more important for the function. Besch
and colleagues have observed sparing of the temporal field
in VGB patients using static perimetry [26]. Nasal pre-
dominance of the VF constriction was also observed by
Midlefart in regard to static perimetry within 60 degrees
of eccentricity [6] and by Daneshvar [27]. Kinirions and
colleagues observed concentric constriction in 52.7% of
the cohort [19], Newman in 20% of examined patients [3]
but they used mean radial degree of III4e [19] or I4e [3] as
an indicator. In our study the prevalence was low com-
pared to that in the above-mentioned studies. In our study
the serial VFs demonstrated inter-weaving of the isopters
at baseline and throughout the subsequent studies, but
there has already been reported a high variability of VF
test in population of epilepsy patients taking VGB [19].
We have shown the usefulness of SKP in epilepsy
patients. It has previously been shown that kinetic per-
imetry is better accepted by patients with neurological
deficits than static perimetry [16]. Peripheral VF loss is
clinically relevant during outdoor activity, as the periph-
eral retina is specialized in detecting moving objects.
The position of isopters in manual kinetic perimetry is
highly influenced by the individual RT of the patient
[28]. RT is the time interval between the onset of the
stimulus and the response. A longer RT shifts the isopter
border towards the direction of stimulus movement.
SKP gives advantage of measuring individual RT during
single VF examination. The RT had not yet been investi-
gated in patients taking VGB, it has been assessed so far
in normal individuals and patients with advanced VF loss
[5,10]. Taking into account other studies dealing with SKP,
RT is prolonged in VGB patients comparing with normal
individuals (370–756 ms) [10] and also in patients with
advanced VF loss (794 ms) due to glaucoma, retinitis pig-
mentosa and hemianopia [29]. Prolongation of RT may
additionally be explained by a decreased alertness in epi-
lepsy patients. It has been shown that VGB treated pa-
tients can be impaired at detecting moving objects in
the periphery, which may be caused by attention and
recognition deficits. Slowing down of response times in
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Naili and co-workers [30]. Correcting the area of isopters
to RT using SKP can eliminate the influence of patients’
fluctuating attention due to seizure activity and the drug
treatment. In previous studies using Goldmann kinetic
perimetry this criterion could have not been considered
due to technological limitations. Delayed RT may mimic
VF constriction under these conditions. Moreover, RT has
been found to be the most important factor influencing
the variability of the response and fatigue during SKP and
can be used as a reliability indictor [31]. As in our study
RT is prolonged in patients receiving VGB and there is
correlation with decreasing isopters’area we can presume,
that there may be high variability of response and fatigue
in VGB patients performing SKP.
Conclusions
In our study there was attenuation of area of III4e, I4e
and I2e isopters during a period of 2 years. We found
that RT, the cumulative dose and the mean daily dose of
VGB influence isopters’ area obtained with SKP. We
suggest performing VF testing prior to VGB treatment if
patients are able to perform the test. Larger studies with
SKP are necessary to explore the history and time course
of the VAVFL.
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